Satsuma Pharmaceuticals, which is developing a fast-acting dry powder nasal spray for migraines, raised $83 million by offering 5.5 million shares at $15, the midpoint of the $14 to $16 range. The company raised 10% more proceeds than expected by selling an additional 500,000 shares. Insiders had indicated on purchasing up to $25 million of the IPO (30% of the deal).
Satsuma Pharmaceuticals plans to list on the Nasdaq under the symbol STSA. Credit Suisse, SVB Leerink and Evercore ISI acted as lead managers on the deal.
Migraine biotech Satsuma Pharmaceuticals prices upsized IPO at $15 midpoint
September 12, 2019

